



ACN 010 126 708

ASX Release
26th May 2017

Chairman's Address to Shareholders

Dear Shareholders,

As per the Company's Annual Report, 2016 was a year of solid progress towards returning shareholder value through the furthering of RHS' product development and a repositioning and expansion of the Company's scope. In particular, it has been an incredible achievement by the RHS team to launch and establish DOPlify™ as a world leading product and to advance our PGS/PGD (Pre-implantation Genetic Screening /Pre-implantation Genetic Diagnosis) capabilities within budget and with a total loss for the financial year of \$1.8m.

The repositioning of the Company over the last year is reflected in the proposed name change simplified to just RHS Ltd accompanied with the tag line Unique Genomic Solutions. There is no doubt that RHS' understanding of the molecular methods used in the IVF industry for PGS/PGD is at least the equal of any other organisation in the world and remains a founding passion in our pipeline of programs. The enabling WGA solution in EmbryoCollect™ evolved into our second product DOPlify™, which is applicable to micro amounts of genetic material that can be as little as a single cell, circulating "free" DNA or other limited genetic material. This product is a platform technology that has very broad applications across diagnostic and clinical medicine and extends into forensics and diverse non-human industries.

RHS has been undervalued but the appreciation of the Company's technology and know-how is growing. The achievements of 2016 were supported through a Rights Issue and placement to sophisticated investors raising \$1.5m to accelerate our programs. We are focused on rewarding shareholders through both revenue growth (pleasingly QOQ growth is occurring – albeit slower than forecast) and furthering corporate relationships with major companies across the genomic industries that are evolving and maturing.

There has been pleasing progress with our relationships and collaborations with significant international companies in relation to the broader application of our technologies to genomic solutions, in particular in the field of liquid biopsy for health screening and cancer management. I look forward to the Company announcing the tangible outcomes of these relationships in the near term.

In relation to our particular interest in improving IVF outcomes through PGS/PGD, RHS continues to be increasingly recognised for our expertise and technologies. We announce today that RHS is in advanced discussions regarding a co-development agreement with Repromed, part of the Monash IVF Group for non-invasive PGS from spent culture medium. The preliminary data has been submitted as a joint abstract for presentation at the American Society for Reproductive Medicine meeting to be

For personal use only

held in San Antonio in October. The project has the potential to lead to a significant increase in PGS through reducing the need for technically demanding embryo biopsy and by making the test more accessible and more affordable.

The RHS PGS service business is steadily growing creating a clinically relevant dataset and most pleasingly leading to live births following use of the RHS products.

RHS has established a reputation for quality and professionalism in our field through persistence and efficiency. The relevance of our technologies is increasingly being understood and I feel confident in saying to shareholders that this will translate into commercially rewarding outcomes.

There are many people to thank for the achievements thus far and as we look at the current year, RHS is positioned to emerge as a stable and significant contributor to the burgeoning genomics industry. In particular, this is an opportunity to draw attention to the continuing efforts of our CEO Dr Michelle Fraser, who provides great expertise and a strong work ethic in her leadership. Our CSO Dr Melinda Jasper and her team are again to be commended for their scientific contributions to our product development and for the professionalism and quality of our PGS services. The Board would also like to thank Mr Ray Ridge for his contribution as Company Secretary and CFO, most ably supported by Ms Oksana Mugalimova.

My thanks to fellow Board members Ms Sue MacLeman and Mr Johnathon Mathews for their contributions over this exciting stage of the Company's development; and to Professor Colin Matthews for his continued input as the Chair of the Scientific and Clinical Committee and as alternate Director for Johnathon. All at RHS are appreciative of the shareholder loyalty that has been demonstrated and the Company is now poised to expand and deliver on commercial objectives.

Dr David Brookes
Chairman

26th May 2017

About RHS

RHS is a developer of advanced single cell genomic technologies focussed on improving health and research outcomes, with over 10 years of technical experience in the field. RHS recently released DOPlify™, a product that is a platform technology for whole genome amplification (WGA) of single or small numbers of cells. DOPlify™ is applicable to the global Next Generation Sequencing (NGS) market. EmbryoCollect™ is the Company's lead IVF specific product and is designed to increase the chance of a successful IVF cycle by selecting the most viable embryos for transfer by screening for aneuploidy. This is known as Preimplantation Genetic Screening (PGS).

Reproductive Health Science Ltd.

ACN 010 126 708
ASX: RHS

Issued Capital

79.2 million shares
6.9 million options

Registered Office

Level One, BioSA Incubator,
40-46 West Thebarton Road,
Thebarton, SA 5031

Tel: +61 8 8152 9348
Fax: +61 8 8152 9474

WEB www.rhsc.com.au

Directors

Dr David Brookes (Chairman)
Sue MacLeman
Johnathon Matthews
Dr Michelle Fraser (CEO)

Finance Officer

& Company Secretary
Raymond Ridge

For personal use only